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Abstract 
 Anxiety is a common problem in dentistry which could affect the correct treatment and involve failure. Oral pre‑
medication is needed to treat several anxious patients. Many people are so highly anxious that oral sedation is not 
effective and need to be under deep sedation or even general anaesthesia in order to receive dental care. In these 
patients, due to a high level of anxiety, even the insertion of an intravenous catheter can be difficult. Benzodiazepines 
have been the most commonly used anxiolytic in these cases, but many may be associated with paradoxical reac‑
tions. Melatonin has a good potential to be used in this field as alternative to benzodiazepines because it may induce 
a natural sleepiness and improve sedation. The purpose of this paper was to summarize what is known about the use 
of melatonin in oral health and as dental premedication in anxious dental patients. Databases were searched for the 
relevant published literature to 30 April 2015. The following search items were used in various combinations: mela‑
tonin, premedication, anxiety, dental, sedation and anaesthesia. Few articles were found about this aspect, and the 
use of melatonin is still a controversial aspect in dental field. More detailed/specific studies are necessary to extend 
the therapeutic possibilities of melatonin as premedication in dentistry.
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Background
There is evidence that phobias, anxiety or dentist fear 
may be related to general health problems. This is an 
important fact if it is considered that more than half of 
patients need to go to the dentist and 20  % avoid it for 
that reason. Dentist’s fear tend to be stable and difficult 
to remove due to the personal experience or anxiety 
induced by feedback from other patients [1]. In highly 
anxious patients, if the treatment is provided under gen-
eral anaesthesia, fear of needles can hamper the place-
ment of an intravenous line or there may be fear of being 
under anaesthesia in addition to the fear owing to the 
dental procedure.
There are different methods of helping patients to 
reduce this sense of fear and anxiety and one of the most 
effective is oral premedication. The most commonly 
used oral anxiolytic medication for patients in dentistry 
has been a drug from the benzodiazepines class, such 
as triazolam, midazolam, lorazepam, and diazepam [2]. 
There are widely known side effects of benzodiazepines 
class, and rejection on several occasions to take the med-
ication. In this sense, substances such as melatonin has 
showed to be as good in anxiolysis as benzodiazepines 
but without most of their side effects [3, 4].
Review
Biology of melatonin and application in oral health
Melatonin (MT) is the principal secretory product of 
the pineal gland and associated with the regulation of 
the circadian dark/light rhythm of the human body. This 
hormone has antioxidant and inmunomodulatory activi-
ties. Additionally, MT does not have any toxicity but is 
an highly lipophilic substance and this property facili-
tates its penetration through cell membranes and com-
partments [5] which suggests that MT could be used 
therapeutically; for instance, locally, (1) in the oral cavity 
damage of mechanical, bacterial, viral and fungal origin, 
(2) in postsurgical wounds caused by tooth extractions 
and other oral surgeries, acting as a promoter of bone 
formation, suppressing inflammation of the gingiva and 
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periodontum, (3) to enhance osteointegration of dental 
implants and in auto-immunological disorders such as 
Sjorgen syndrome, herpes lesions, aphthous ulceration, 
lichen planus and (4) even to limit oral cancer [6]. In this 
sense, the beneficial effects of MT in oral health could be 
several such as the reduction of severity of herpes, that 
have proven to be at least as effective as drug Acyclovir, 
and although it is unclear mechanism of action, it could 
be due to stimulation of NK CD4 cells [7]. Melatonin in 
oral health could be considered as a prognostic marker 
for oral pathologies like cancer. Low plasma levels of 
MT is associated to oral cancer, while MT could be con-
sidered as an oncostatic agent of several types of can-
cer: such as lung cancer, breast, gastric, colon which are 
linked by low plasma levels of MT, too [7].
MT gets to the saliva by passive diffusion from the 
blood. This is why the concentration of MT in saliva was 
reported to be about 30 % of that in the plasma [8]. The 
amount of MT in saliva is lower when compared to blood 
value probably due to the fact that nearly 70  % of the 
plasma MT is bound to albumin and this prevents its free 
diffusion into saliva.
Local MT administration reports a lot of potential 
effects in the oral cavity [9] and may contribute to the 
regeneration of alveolar bone through the stimulation of 
type I collagen fiber production and modulation of osteo-
blastic and osteoclastic activity.
It should be considered that MT from the blood into 
the saliva may play an important role in suppressing oral 
diseases and have beneficial effects in periodontal dis-
ease, herpes and oral cancer [10] and the importance of 
MT in the prognosis and treatment of certain tumours, 
like epidermoid carcinoma [7].
Premedication in dentistry
Oral sedation can be beneficial in dentistry due to the 
fact that it decreases activity, moderates excitement, and 
calms the patient. While barbiturates were effective at 
sedation, they had certain undesirable side effects, such 
as potential for addiction, cardiovascular and respiratory 
depression, and a low therapeutic index. Barbiturate use 
was eventually replaced by benzodiazepines for seda-
tion due to their wide margin of safety and effectiveness 
in sedation, anxiolysis, and amnesia. Furthermore, addi-
tional care must be taken in patients with cardiovascular, 
respiratory, renal or hepatic disease [11].
The use of melatonin sublingually (0.05  mg  kg−1 or 
5  mg) was shown to be associated with preoperative 
anxiolysis in adults without psychomotor impairment or 
impact on recovery. The melatonin has other advantages 
such as: (1) it is difficult to overdose, since it is a naturally 
occurring hormone, (2) it may also be more acceptable 
by patients that may be uncomfortable intaking synthetic 
medications and (3) it has a relatively short half-life, so 
prolonged sedation is less likely than with benzodiaz-
epines [4, 12].
Use of MT is generally safe without significant adverse 
effect in healthy adults over the age of 18 years old, who 
are not pregnant and without psychiatric disorders, and 
the only one short-term side effect from oral adminis-
tration of exogenous melatonin is sleepiness, but conse-
quences of a long-term melatonin use are still unknown.
Exogenous melatonin and its use in dentirsty
The way that MT exerts its anaesthetic effect is similar to 
other anaesthetics such as propofol and benzodiazepines, 
increasing the binding of GABA to the GABAa recep-
tor, because binding of melatonin to the MT1 receptor 
appears to affect the GABAa receptor via the G-coupled 
protein pathway [13].
Exogenous melatonin is rapidly absorbed and peak 
plasma levels are reached in 60–150 min. The elimination 
half-life of melatonin is about 12–48 min. Melatonin has 
a hypnotic/sedative effect when administered orally [3]. 
This may be due to its circadian rhythm regulation effect. 
Sublingual administration of melatonin prior to general 
anaesthesia produce sedation and anxiolysis comparable 
to sublingual midazolam in adult women, which is signif-
icantly different compared to placebo [13].
Melatonin premedication, in an oral dose of either 3 or 
5 mg, reduce the required dose of propofol to achieve a 
bispectral index score 45, reflecting a sufficient level of 
hypnosis for tracheal intubation without prolongation of 
postoperative recovery room stay [14] and is associated 
with faster recovery times and less incidence of postop-
erative excitement and sleep disturbances 2 weeks post-
operatively in comparison with midazolam [15].
In a recently published review to assess the effect of 
melatonin on pre- and postoperative anxiety in adults, 
when compared MT given as premedication to placebo, 
melatonin can reduce preoperative anxiety 50–100  min 
after administration and MT may be equally as effective 
as standard treatment with midazolam in reducing pre-
operative anxiety (50–100  min after administration) in 
adults [16]. Unlike midazolam, oral melatonin does not 
impair the general cognitive and psychomotor functions 
[17].
Melatonin may reduce postoperative anxiety in adults 6 
hours after surgery compared to placebo, but its effect is 
mixed and an overall attenuation of the effect compared 
to preoperatively is suggested [16]. Oral MT seems pre-
vent postoperative agitation in children who need general 
anaesthesia for oesophageal dilatation procedures [18].
A randomized controlled factorial trial suggested that 
adition of MT to alprazolam produces superior anxiolysis 
compared with either drugs alone or placebo [19].
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There is very little investigation on melatonin to reduce 
anxiety for dental treatment. Only one paper showed 
similar results when MT is used as dental premedica-
tion in children compared with placebo [20]. The possible 
reason is that perhaps melatonin cannot induce hypno-
sis/sedation at a high enough level in very anxious dental 
patients to accept its use as an universal oral premedi-
cation. However, comparing MT with other substances 
such as benzodiazepines (the current gold standard), 
it seems that melatonin has good potential to be used 
for reducing anxiety and producing sedation in dental 
patients undergoing general anaesthesia without any sig-
nificant adverse effect.
Concluding, further experimental studies are needed 
about functions of melatonin in the oral cavity. MT can 
be effective provided it is used in a right population and 
situation but more specific/detailed studies are necessary 
to extend the therapeutic possibilities of melatonin as 
premedication in dentistry.
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